Aurinia Pharmaceuticals

AUPHNASDAQ
$5.61
0.142.56%
At Close: -
$5.55
-0.06-1.04%
After Hours: Jul 5, 7:41 PM EDT
15 minutes delayed
Aurinia Pharmaceuticals (AUPH) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Outperform
Highest Price Target1
$13.00
Lowest Price Target1
$8.00
Consensus Price Target1
$8.60

want to know what
the Bulls & Bears Say?

Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock, Analyst Ratings, Price Targets, Forecasts

Aurinia Pharmaceuticals Inc has a consensus price target of $8.6 based on the ratings of 28 analysis. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Cantor Fitzgerald, and HC Wainwright & Co. on March 1, 2024, February 23, 2024, and February 22, 2024, respectively. With an average price target of $12 between HC Wainwright & Co., Cantor Fitzgerald, and HC Wainwright & Co., there's an implied 116.16% upside for Aurinia Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Feb
0
0
0
0
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.6
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Cantor Fitzgerald
RBC Capital
Oppenheimer
SVB Leerink

1calculated from analyst ratings

Analyst Ratings for Aurinia Pharmaceuticals

Buy NowGet Alert
03/01/2024Buy Now134.17%HC Wainwright & Co.
Ed Arce
 → $13ReiteratesBuy → BuyGet Alert
02/23/2024Buy Now80.13%Cantor Fitzgerald
Olivia Brayer
$12 → $10MaintainsOverweightGet Alert
02/22/2024Buy Now134.17%HC Wainwright & Co.
Ed Arce
$15 → $13MaintainsBuyGet Alert
02/16/2024Buy Now44.11%RBC Capital
Douglas Miehm
$13 → $8MaintainsOutperformGet Alert
09/22/2023Buy Now170.2%HC Wainwright & Co.
Ed Arce
 → $15ReiteratesBuy → BuyGet Alert
08/07/2023Buy Now170.2%HC Wainwright & Co.
Ed Arce
$14 → $15MaintainsBuyGet Alert
07/06/2023Buy Now170.2%Cantor Fitzgerald
Olivia Brayer
 → $15ReiteratesOverweight → OverweightGet Alert
05/03/2023Buy Now152.18%HC Wainwright & Co.
Ed Arce
 → $14Reiterates → BuyGet Alert
02/23/2023Buy Now98.14%RBC Capital
Douglas Miehm
 → $11Reiterates → OutperformGet Alert
01/04/2023Buy Now98.14%RBC Capital
Douglas Miehm
$10 → $11MaintainsOutperformGet Alert
11/07/2022Buy Now152.18%HC Wainwright & Co.
Ed Arce
$26 → $14MaintainsBuyGet Alert
11/04/2022Buy Now80.13%RBC Capital
Douglas Miehm
$18 → $10MaintainsOutperformGet Alert
11/04/2022Buy Now—Oppenheimer
Justin Kim
—DowngradeOutperform → PerformGet Alert
11/04/2022Buy Now116.16%SVB Leerink
Joseph Schwartz
$17 → $12MaintainsOutperformGet Alert
08/09/2022Buy Now368.34%HC Wainwright & Co.
Ed Arce
$30 → $26MaintainsBuyGet Alert
08/08/2022Buy Now134.17%Oppenheimer
Justin Kim
$15 → $13MaintainsOutperformGet Alert
05/05/2022Buy Now350.33%Cantor Fitzgerald
Olivia Brayer
 → $25Assumes → OverweightGet Alert
05/05/2022Buy Now440.39%HC Wainwright & Co.
Ed Arce
$33 → $30MaintainsBuyGet Alert
04/28/2022Buy Now296.29%RBC Capital
Douglas Miehm
$27 → $22MaintainsOutperformGet Alert
03/08/2022Buy Now296.29%SVB Leerink
Joseph Schwartz
$30 → $22MaintainsOutperformGet Alert
03/01/2022Buy Now386.36%RBC Capital
Douglas Miehm
$31 → $27MaintainsOutperformGet Alert
02/23/2022Buy Now458.41%RBC Capital
Douglas Miehm
$34 → $31MaintainsOutperformGet Alert
12/10/2021Buy Now458.41%Oppenheimer
Justin Kim
—UpgradePerform → OutperformGet Alert
11/04/2021Buy Now494.43%Oppenheimer
Justin Kim
—MaintainsPerformGet Alert
11/04/2021Buy Now620.53%HC Wainwright & Co.
Ed Arce
—MaintainsBuyGet Alert
11/04/2021Buy Now530.46%SVB Leerink
Joseph Schwartz
—MaintainsOutperformGet Alert
10/28/2021Buy Now476.42%Oppenheimer
Justin Kim
—DowngradeOutperform → PerformGet Alert
10/26/2021Buy Now512.45%RBC Capital
Douglas Miehm
—MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Aurinia Pharmaceuticals (AUPH) stock?

A

The latest price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) was reported by HC Wainwright & Co. on March 1, 2024. The analyst firm set a price target for $13.00 expecting AUPH to rise to within 12 months (a possible 134.17% upside). 6 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Aurinia Pharmaceuticals (AUPH)?

A

The latest analyst rating for Aurinia Pharmaceuticals (NASDAQ:AUPH) was provided by HC Wainwright & Co., and Aurinia Pharmaceuticals reiterated their buy rating.

Q

When was the last upgrade for Aurinia Pharmaceuticals (AUPH)?

A

The last upgrade for Aurinia Pharmaceuticals Inc happened on December 10, 2021 when Oppenheimer raised their price target to $31. Oppenheimer previously had a perform for Aurinia Pharmaceuticals Inc.

Q

When was the last downgrade for Aurinia Pharmaceuticals (AUPH)?

A

The last downgrade for Aurinia Pharmaceuticals Inc happened on November 4, 2022 when Oppenheimer changed their price target from N/A to N/A for Aurinia Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Aurinia Pharmaceuticals (AUPH)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aurinia Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aurinia Pharmaceuticals was filed on March 1, 2024 so you should expect the next rating to be made available sometime around March 1, 2025.

Q

Is the Analyst Rating Aurinia Pharmaceuticals (AUPH) correct?

A

While ratings are subjective and will change, the latest Aurinia Pharmaceuticals (AUPH) rating was a reiterated with a price target of $0.00 to $13.00. The current price Aurinia Pharmaceuticals (AUPH) is trading at is $5.55, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.